content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Caladrius Biosciences (CLBS)

5.95
-0.55
(-8.46%)
Sep 11, 4:00PM EDT
content_middle

Caladrius (CLBS) the former NeoStem engages in the development of proprietary cell therapy products.

Caladrius Biosciences, Inc. is a clinical stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications.

CLBS is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes, in an ongoing Phase 2 trial. 

CLBS14, a CD34+ cell therapy intended as a treatment for coronary microvascular dysfunction, is Caladrius’ proprietary and patent protected formulation of CD34 cells designed specifically to enhance the potency of the CD34 cells for repair and regeneration of cardiovascular tissue. Its companion product, CLBS12, is specifically formulated for intramuscular administration for the treatment of lower extremity ischemia. 

A phase 2 study of CLBS12 as a treatment for critical limb ischemia recently was initiated in Japan, a successful outcome of which will qualify the program for consideration of early conditional approval based on discussions with the Japanese regulatory authorities as provided for under Japan’s progressive regenerative medicine regulations.

Founded as NeoStem in 1980, CLBS is headquartered in Basking Ridge, NJ.

Previous Close: 
3.99
Open: 
3.95
Bid: 
3.70
Ask: 
4.07
1yr Target Price: 
5.00
Day's Range: 
3.85 - 4.08
52wk Range: 
2.63 - 11.65
Volume: 
39033
Average Daily Volume: 
30170
Market Capitalization: 
57.87M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
9.73M
content_right

Pages